CVM Quote, Financials, Valuation and Earnings

IGC Pharma has a net margin of -- compared to CEL-SCI's net margin of -711.67%. CEL-SCI's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 9985.04%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1163.86%. Given that CEL-SCI has higher upside potential than IGC Pharma, analysts believe CEL-SCI is more attractive than IGC Pharma.

CEL-SCI has a beta of 0.271, which suggesting that the stock is 72.891% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.479, suggesting its more volatile than the S&P 500 by 47.852%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. CEL-SCI's net income of -$6.6M is lower than IGC Pharma's net income of -$1.8M. Notably, CEL-SCI's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 18.03x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to CEL-SCI's net margin of 21.68%. CEL-SCI's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 9985.04%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 23.65%. Given that CEL-SCI has higher upside potential than Eli Lilly and, analysts believe CEL-SCI is more attractive than Eli Lilly and.

CEL-SCI has a beta of 0.271, which suggesting that the stock is 72.891% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.73% to investors and pays a quarterly dividend of $1.50 per share. CEL-SCI pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CEL-SCI quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. CEL-SCI's net income of -$6.6M is lower than Eli Lilly and's net income of $2.8B. Notably, CEL-SCI's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 62.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 14.19x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

OS Therapies has a net margin of -- compared to CEL-SCI's net margin of --. CEL-SCI's return on equity of -- beat OS Therapies's return on equity of --.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 9985.04%. On the other hand OS Therapies has an analysts' consensus of $13.50 which suggests that it could grow by 708.38%. Given that CEL-SCI has higher upside potential than OS Therapies, analysts believe CEL-SCI is more attractive than OS Therapies.

CEL-SCI has a beta of 0.271, which suggesting that the stock is 72.891% less volatile than S&P 500. In comparison OS Therapies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OS Therapies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. OS Therapies pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than OS Therapies quarterly revenues of --. CEL-SCI's net income of -$6.6M is lower than OS Therapies's net income of -$3.9M. Notably, CEL-SCI's price-to-earnings ratio is -- while OS Therapies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus -- for OS Therapies. Usually stocks with elevated PS ratios are considered overvalued.

Vigil Neuroscience has a net margin of -- compared to CEL-SCI's net margin of --. CEL-SCI's return on equity of -- beat Vigil Neuroscience's return on equity of --.

CEL-SCI has a consensus price target of $8.00, signalling upside risk potential of 9985.04%. On the other hand Vigil Neuroscience has an analysts' consensus of $9.52 which suggests that it could grow by 20.87%. Given that CEL-SCI has higher upside potential than Vigil Neuroscience, analysts believe CEL-SCI is more attractive than Vigil Neuroscience.

CEL-SCI has a beta of 0.271, which suggesting that the stock is 72.891% less volatile than S&P 500. In comparison Vigil Neuroscience has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vigil Neuroscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. Vigil Neuroscience pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than Vigil Neuroscience quarterly revenues of --. CEL-SCI's net income of -$6.6M is higher than Vigil Neuroscience's net income of -$22.4M. Notably, CEL-SCI's price-to-earnings ratio is -- while Vigil Neuroscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus -- for Vigil Neuroscience. Usually stocks with elevated PS ratios are considered overvalued.